LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Home・Akcijų sąrašas・Microbot Medical Inc

Microbot Medical Inc

Uždarymo kaina

2.1 -3.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.03

Max

2.21

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-77K -3.6M
Darbuotojai	20
EBITDA	-79K -3.6M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+245.62% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-23

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	5.4M 146M
Ankstesnė atidarymo kaina	5.33
Ankstesnė uždarymo kaina	2.1

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

2.52 / 2.57 Palaikymas ir pasipriešinimas

Microbot Medical Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-17 23:44; UTC

Karštos akcijos

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

2026-02-17 23:20; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

2026-02-17 22:57; UTC

Uždarbis

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 21:59; UTC

Uždarbis

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

2026-02-17 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-02-17 23:54; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-17 23:45; UTC

Rinkos pokalbiai

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

2026-02-17 23:19; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 23:15; UTC

Uždarbis

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:58; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

2026-02-17 22:58; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

2026-02-17 22:57; UTC

Įsigijimai, susijungimai, perėmimai

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

2026-02-17 22:50; UTC

Įsigijimai, susijungimai, perėmimai

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

2026-02-17 22:44; UTC

Uždarbis

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

2026-02-17 22:42; UTC

Uždarbis

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

2026-02-17 22:36; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

2026-02-17 22:36; UTC

Uždarbis

Santos Final Dividend 10.3 U.S. Cents/Security

2026-02-17 22:36; UTC

Uždarbis

Santos FY Underlying Profit US$898 Million, Down 25%

2026-02-17 22:35; UTC

Uždarbis

Santos FY Revenue US$4.94 Billion, Down 8%

2026-02-17 22:35; UTC

Uždarbis

Correct: Santos FY Net Profit US$818 Million, Down 33%

2026-02-17 22:35; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

2026-02-17 22:34; UTC

Uždarbis

Santos FY Net Profit US$818 Billion, Down 33%

2026-02-17 22:02; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

2026-02-17 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

2026-02-17 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-02-17 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-17 21:49; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

2026-02-17 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

Akcijų palyginimas

Kainos pokytis

Microbot Medical Inc Prognozė

Kainos tikslas

By TipRanks

245.62% į viršų

12 mėnesių prognozė

Vidutinis 7.5 USD 245.62%

Aukščiausias 12 USD

Žemiausias 5 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Microbot Medical Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Microbot Medical Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

2.52 / 2.57Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.